2nd Quarter - Report

ALEXION PHARMACEUTICALS, INC. for ALEXION PHARMACEUTICALS, INC.

Firm
Client
Income
—
Expenses
$105,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Korea FTA

LobbyistCovered position, as disclosed
HEIDI L WAGNER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Health Issues HCR

Monitor implementation of PPACA, including provisions relating to orphan drugs and regulatory pathway for biosimilars. Monitor deficit reduction initiatives.

LobbyistCovered position, as disclosed
HEIDI L WAGNER —

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.